Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis



      The aim of the present study was to evaluate the efficacy of an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) in patients with progressive multiple sclerosis (MS).


      This accelerated proof-of-concept study consisted of 2 phases: a crossover challenge (dose-finding) phase and a 4-week, parallel, randomized, placebo-controlled treatment phase. Twenty-four patients with progressive MS and moderate spasticity were enrolled. During the treatment phase, biomarkers for efficacy and secondary pharmacodynamic effects were measured at baseline and after 2 and 4 weeks of treatment. Serum samples were collected to determine pharmacokinetic properties and perform population modeling. Safety and tolerability profiles were assessed based on adverse events and safety measurements.


      Pain was significantly reduced when measured directly after administration of ECP002A in the clinic but not when measured in a daily diary. A similar pattern was observed in subjective muscle spasticity. Other clinical outcomes were not significantly different between active treatment and placebo. Cognitive testing indicated that there was no decline in cognition after 2 or 4 weeks of treatment attributable to ECP002A compared with placebo.
      This study specifically underlines the added value of thorough investigation of pharmacokinetic and pharmacodynamic associations in the target population. Despite the complex interplay of psychoactive effects and analgesia, the current oral formulation of Δ9-tetrahydrocannabinol may play a role in the treatment of spasticity and pain associated with MS because it was well tolerated and had a stable pharmacokinetic profile.

      Key words

      To read this article in full you will need to make a payment
      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Compston A.
        • Ebers G.
        • Lassmann H.
        • et al.
        McAlpine׳s multiple sclerosis. Third edition. Churchill Livingstone, London1998
        • Paisley S.
        • Beard S.
        • Hunn A.
        • Wight J.
        Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review.
        Mult Scler. 2002; 8: 319-329
        • Solaro C.
        • Brichetto G.
        • Amato M.P.
        • et al.
        The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study.
        Neurology. 2004; 63: 919-921
        • Jean-Gilles L.
        • Feng S.
        • Tench C.R.
        • et al.
        Plasma endocannabinoid levels in multiple sclerosis.
        J Neurol Sci. 2009; 287: 212-215
        • Scotter E.L.
        • Abood M.E.
        • Glass M.
        The endocannabinoid system as a target for the treatment of neurodegenerative disease.
        Br J Pharmacol. 2010; 160: 480-498
        • Collin C.
        • Davies P.
        • Mutiboko I.K.
        • Ratcliffe S.
        Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
        Eur J Neurol. 2007; 14: 290-296
        • Iversen L.
        Cannabis and the brain.
        Brain. 2003; 126: 1252-1270
        • Schlicker E.
        • Kathmann M.
        Modulation of transmitter release via presynaptic cannabinoid receptors.
        Trends Pharmacol Sci. 2001; 22: 565-572
        • Zajicek J.
        • Fox P.
        • Sanders H.
        • et al.
        Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
        Lancet. 2003; 362: 1517-1526
        • Rog D.J.
        Cannabis-based medicines in multiple sclerosis--a review of clinical studies.
        Immunobiology. 2010; 215: 658-672
        • Lakhan S.E.
        • Rowland M.
        Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.
        BMC Neurol. 2009; 9: 59
        • Svendsen K.B.
        • Jensen T.S.
        • Bach F.W.
        Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? randomised double blind placebo controlled crossover trial.
        BMJ. 2004; 329: 253
        • Killestein J.
        • Hoogervorst E.L.
        • Reif M.
        • et al.
        Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
        Neurology. 2002; 58: 1404-1407
        • Klumpers L.E.
        • Beumer T.L.
        • van Hasselt J.G.
        • et al.
        Novel Delta(9) -tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects.
        Br J Clin Pharmacol. 2012; 74: 42-53
        • Polman C.H.
        • Reingold S.C.
        • Edan G.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”.
        Ann Neurol. 2005; 58: 840-846
        • Eisen A.
        Electromyography in disorders of muscle tone.
        Can J Neurol Sci. 1987; 14: 501-505
        • Matthews W.B.
        Ratio of maximum H reflex to maximum M response as a measure of spasticity.
        J Neurol Neurosurg Psychiatry. 1966; 29: 201-204
        • Bowdle T.A.
        • Radant A.D.
        • Cowley D.S.
        • et al.
        Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.
        Anesthesiology. 1998; 88: 82-88
        • Bond A.
        • Lader M.
        The use of analogue scales in rating subjective feelings.
        Br J Med Psychol. 1974; 47: 211-218
        • Bohannon R.W.
        • Smith M.B.
        Interrater reliability of a modified Ashworth scale of muscle spasticity.
        Phys Ther. 1987; 67: 206-207
        • Penn R.D.
        Intrathecal baclofen for severe spasticity.
        Ann N Y Acad Sci. 1988; 531: 157-166
        • Farrar J.T.
        • Young Jr, J.P.
        • LaMoreaux L.
        • et al.
        Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
        Pain. 2001; 94: 149-158
        • Melzack R.
        The short-form McGill Pain Questionnaire.
        Pain. 1987; 30: 191-197
        • Wright K.D.
        • Asmundson G.J.
        • McCreary D.R.
        Factorial validity of the short-form McGill pain questionnaire (SF-MPQ).
        Eur J Pain. 2001; 5: 279-284
        • Bolton J.E.
        • Wilkinson R.C.
        Responsiveness of pain scales: a comparison of three pain intensity measures in chiropractic patients.
        J Manipulative Physiol Ther. 1998; 21: 1-7
        • Kurtzke J.F.
        Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33: 1444-1452
        • Buysse D.J.
        • Reynolds III, C.F.
        • Monk T.H.
        • et al.
        The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.
        Psychiatry Res. 1989; 28: 193-213
        • Cohen J.A.
        • Fischer J.S.
        • Bolibrush D.M.
        • et al.
        Intrarater and interrater reliability of the MS functional composite outcome measure.
        Neurology. 2000; 54: 802-806
        • Krupp L.B.
        • LaRocca N.G.
        • Muir-Nash J.
        • Steinberg A.D.
        The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.
        Arch.Neurol. 1989; 46: 1121-1123
        • Wilson W.H.
        • Ellinwood E.H.
        • Mathew R.J.
        • Johnson K.
        Effects of marijuana on performance of a computerized cognitive-neuromotor test battery.
        Psychiatry Res. 1994; 51: 115-125
        • Strougo A.
        • Zuurman L.
        • Roy C.
        • et al.
        Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids.
        J Psychopharmacol. 2008; 22: 717-726
        • Chohan H.
        • Greenfield A.L.
        • Yadav V.
        • Graves J.
        Use of Cannabinoids for Spasticity and Pain Management in MS.
        Curr Treat Options Neurol. 2016; 18: 1
        • Beard S.
        • Hunn A.
        • Wight J.
        Treatments for spasticity and pain in multiple sclerosis: a systematic review.
        Health Technol Assess. 2003; 7: 111
        • Vaney C.
        • Heinzel-Gutenbrunner M.
        • Jobin P.
        • et al.
        Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
        Mult Scler. 2004; 10: 417-424
        • Thaera G.M.
        • Wellik K.E.
        • Carter J.L.
        • et al.
        Do cannabinoids reduce multiple sclerosis-related spasticity?.
        Neurologist. 2009; 15: 369-371
        • Centonze D.
        • Mori F.
        • Koch G.
        • et al.
        Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
        Neurol Sci. 2009; 30: 531-534
        • Leocani L.
        • Nuara A.
        • Houdayer E.
        • et al.
        Sativex((R)) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
        J Neurol. 2015; 262: 2520-2527
        • Russo M.
        • Calabro R.S.
        • Naro A.
        • et al.
        Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
        Neural Plast. 2015; 2015: 656582
        • Kumru H.
        • Murillo N.
        • Samso J.V.
        • et al.
        Reduction of spasticity with repetitive transcranial magnetic stimulation in patients with spinal cord injury.
        Neurorehabil Neural Repair. 2010; 24: 435-441
        • Croxford J.L.
        Therapeutic potential of cannabinoids in CNS disease.
        CNS Drugs. 2003; 17: 179-202
        • Heuberger J.A.
        • Guan Z.
        • Oyetayo O.O.
        • et al.
        Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.
        Clin Pharmacokinet. 2015; 54: 209-219
        • McGilveray I.J.
        Pharmacokinetics of cannabinoids.
        Pain Res Manag. 2005; 10: 15A-22A
        • el-Maghraby T.A.
        • Shalaby N.M.
        • Al-Tawdy M.H.
        • Salem S.S.
        Gastric motility dysfunction in patients with multiple sclerosis assessed by gastric emptying scintigraphy.
        Can J Gastroenterol. 2005; 19: 141-145
        • Chohan H.
        • Greenfield A.L.
        • Yadav V.
        • Graves J.
        Use of Cannabinoids for Spasticity and Pain Management in MS.
        Curr Treat.Options Neurol. 2016; 18: 1
        • Whiting P.F.
        • Wolff R.F.
        • Deshpande S.
        • et al.
        Cannabinoids for medical use: a systematic review and meta-analysis.
        JAMA. 2015; 313: 2456-2473